Last Chance to Lunch with Silicon Valley Movers & Shakers

The final round of bidding on auctions by Motion To Dismiss Cancer began on June 4 and will end on June 7.

Motion To Dismiss Cancer is a fundraising team created to raise money for the Leukemia & Lymphoma Society
. They do so by holding auctions under the heading of "2012 Venture Capital Master's Lunch Series", in which anyone can bid to win private meetings with some of Silicon Valley's top venture capitalists and start-up founders, with all the proceeds supporting the LLS

The three remaining auctions are:

Dinner with Sean Parker

A dinner hosted by Sean Parker with the winning bidder and three of his or her friends at Gary Danko in San Francisco. The winning bidders also receive a two-night stay at the Fairmont San Francisco Hotel.

Sean Parker's credentials:

-- Founding President of Facebook
-- Co-founder of Napster, Plaxo, Causes, and Airtime.
-- Managing partner at the San Francisco-based venture capital fund the Founders Fund.
-- Early investor in Spotify

Jam session with Gina Bianchini

A working lunch and "jam session" hosted by Gina Bianchini, Jason Putorti, and Brian Chesky. The winner can learn important tips on creating a successful design culture, receive feedback on product and strategy, and simply score valuable time with three of the most highly sought after advisors in Silicon Valley.

Gina Bianchini's credentials:
-- Early pioneer in social software, co-founder of Ning, the first and largest social platform for interests and passions online.
-- CEO and founder of Mightybell

Jason Putorti's credentials:

-- Co-founder of Votizen a consumer Internet company working to disrupt the $10B American political industry by delivering votes to candidates at lower cost through social media.
-- Founder advisor to SV Angel
-- Lead designer behind
-- Designer-in-Residence at Bessemer Venture Partners

Brian Chesky's credentials:
-- Co-founder and CEO of Airbnb

Meet Larry Marcus

This auction gives the winning bidder a chance to talk strategy and development with Larry Marcus, Managing Director at Walden Venture Capital and J Sider, founder and CEO of BandPage at BandPage HQ.

J Sider's credentials:
-- Founder and CEO of BandPage, the #1 music app on Facebook
-- Named to Forbes "30 Under 30" in 2011.

Larry Marcus' credentials:
-- Early investor in and fomer board member with Pandora
-- Director at SoundHound
-- Director of BandPage on Facebook
-- Board Observer at PowerCloud Systems
-- Member of the Advisory Council for Industry Ventures

You can learn more by checking out the auctions at
You can also learn more by contacting Christina Resasco at (415) 724-7882

Source: PR Web

More Articles

More Articles is pleased to have the Lymphoma Information Network in the family of associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...